HOME    mypage    Japanese    library    university    Feedback

沖縄地域学リポジトリ >
Ryukyu Medical Association >
Ryukyu Medical Journal >

Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12001/24357

 
Title :A case of rectal cancer in which the administration of mFOLFOX6 plus cetuximab might have caused duodenal perforation
Authors :Teruya, Tsuyoshi
Asato, Masaya
Takushi, Yasukatsu
Nakachi, Atsushi
Authors affiliation :Department of Surgery, Tomishiro Central Hospital
Issue Date :2018
Publisher :琉球医学会
Type Local :雑誌掲載論文
Type (NII) :Journal Article
ISSN :1346-888X
Abstract :Although cetuximab-containing chemotherapies are effective treatments for unresectable advanced colorectal cancer, characteristic side effects have been reported. Here, we report a case of rectal cancer in which duodenal perforation is likely to have occurred during the administration of mFOLFOX6 plus cetuximab as first-line chemotherapy. A 55-year-old woman complained of abdominal pain for several months. She was diagnosed with advanced rectal cancer and unresectable multiple liver and lung metastases. We initiated first-line chemotherapy with mFOLFOX6 plus cetuximab, which was administered with the expectation of early tumor shrinkage and consequent reductions in her abdominal pain. After 2 courses of chemotherapy, her abdominal symptom improved. However, after 4 courses of chemotherapy, she suddenly reported severe abdominal pain and was conveyed to our department. Abdominal computed tomography revealed intraabdominal free air, which we suspected was caused by gastrointestinal perforation. Urgent laparotomy was performed. We identified the perforation at the anterior wall of the duodenal bulb, closed the perforated site, and covered it with the omentum. In general, it has been reported that chemotherapy with cetuximab regimen is associated with some adverse events such as hematotoxicity, acne-like rash and hypersensitivity reaction. This time, we experienced a rare case of duodenal perforation that might have been associated with mFOLFOX6 plus cetuximab. We suggest that bowel perforation should be considered if a patient experiences sudden abdominal pain when receiving chemotherapy.
Rights :琉球医学会
URI :http://hdl.handle.net/20.500.12001/24357
Citation :琉球医学会誌 = Ryukyu Medical Journal Vol.37 no.1-4 p.97 -104
Appears in Collections:Ryukyu Medical Journal

Files in This Item:

File Description SizeFormat
Vol37(1-4)p97.pdf1215KbAdobe PDFView/Open